of Project 2 Hemophilia, an inherited bleeding disorder, is currently treated by protein replacement therapy that provides only transient correction and is a significant financial burden due to the need for frequent infusions. For those with access to concentrate, the most serious complication in the management of the disorder is the development of neutralizing antibodies to the infused factor that occur in up to 30% of those with hemophilia A. For such patients, control of bleeds by infusion of high-dose recombinant activated Factor Vll (rFVlla) results in effective liemostasis. However, this treatment carries a substantial cost due to the short half-life of the protein and the need for repeated dosing. To address these shortcomings we previously developed a novel gene transfer approach whereby we can effect hemostasis using a FVII transgene, engineered to be secreted in the active, two chain form (FVIIa). Using the liver as the target tissue, we demonstrated that continuous expression of FVlla following adeno-associated virus (AAV) gene transfer can correct the phenotypic defect in hemophilic mice and dogs. This approach has immunological advantages over Factor IX (FIX) or Factor Vlll (FVlll) gene strategies since the recipient is tolerant to the transgene product. Moreover it can effect hemostasis even in the face of neutralizing antibodies to FVIII or FIX. Additionally, since rFVlla is used for hemostasis management for other coagulation defects (such a platelet disorders), in contrast to FVIII/FIX gene-based approaches, FVIIa gene transfer may unify the treatment of several coagulation defects to a single product. However, a substantial proportion of hemophilia patients have advanced liver disease due to viral hepatitis, thus rendering the liver an unsuitable tissue for viral vector-mediated gene transfer. We developed a method for transducing extensive areas of muscle by an AAV vector expressing biologically active canine FIX and demonstrated multi- year hemostatic efficacy in hemophilia B dogs. Therefore, as a theme for this project, we propose to use skeletal muscle as the target tissue for expression and secretion of FVlla, using the canine model(s) of hemophilia that closely mimic the human condition. Initially, we wish to perform a systematic study of promoters and AAV serotypes for muscle expression of FVlla, and study the hemostatic efficacy and safety of canine FVlla (cFVlla) expression under optimal conditions, including dogs with inhibitors (Aim 1). In subsequent experiments, we will determine the therapeutic index of a variant of cFVlla with increased activity, as a means to reduce the effective vector dose/viral load per cell and thus address any potential limitations of muscle to perform post-translational modifications necessary for cFVlla biological activity, due to increased antigen expression (Aim 2). Lastly, we will develop a regulated system for cFVlla expression from muscle via a small, orally bioavailable drug (doxycycline) that will enhance the safety of FVIIa gene transfer (Aim 3). Overall, the experiments proposed in the project will establish in a comprehensive manner the pre-clinical basis for muscle-derived FVlla gene transfer.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL064190-13
Application #
8502301
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
13
Fiscal Year
2013
Total Cost
$430,683
Indirect Cost
$141,439
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Sauna, Zuben E; Lozier, Jay N; Kasper, Carol K et al. (2015) The intron-22-inverted F8 locus permits factor VIII synthesis: explanation for low inhibitor risk and a role for pharmacogenomics. Blood 125:223-8
Sullivan, Spencer K; Mills, Jason A; Koukouritaki, Sevasti B et al. (2014) High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. Blood 123:753-7
Sherman, Alexandra; Schlachterman, Alexander; Cooper, Mario et al. (2014) Portal vein delivery of viral vectors for gene therapy for hemophilia. Methods Mol Biol 1114:413-26
Yazicioglu, Mustafa N; Monaldini, Luca; Chu, Kirk et al. (2013) Cellular localization and characterization of cytosolic binding partners for Gla domain-containing proteins PRRG4 and PRRG2. J Biol Chem 288:25908-14
Callejas, David; Mann, Christopher J; Ayuso, Eduard et al. (2013) Treatment of diabetes and long-term survival after insulin and glucokinase gene therapy. Diabetes 62:1718-29
Siner, Joshua I; Iacobelli, Nicholas P; Sabatino, Denise E et al. (2013) Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood 121:4396-403
Mingozzi, Federico; High, Katherine A (2013) Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 122:23-36
Anguela, Xavier M; Sharma, Rajiv; Doyon, Yannick et al. (2013) Robust ZFN-mediated genome editing in adult hemophilic mice. Blood 122:3283-7
Buchlis, George; Podsakoff, Gregory M; Radu, Antonetta et al. (2012) Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 119:3038-41
Mingozzi, Federico; High, Katherine A (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12:341-55

Showing the most recent 10 out of 39 publications